scholarly article | Q13442814 |
P2093 | author name string | Georg Wensing | |
Reiner Frey | |||
Sigrun Unger | |||
Wolfgang Mück | |||
Corina Becker | |||
Soundos Saleh | |||
P2860 | cites work | NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential | Q24656131 |
Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations | Q30449094 | ||
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension | Q33163081 | ||
Riociguat for the treatment of pulmonary arterial hypertension | Q33163083 | ||
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). | Q34666291 | ||
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). | Q34667642 | ||
NO-independent, haem-dependent soluble guanylate cyclase stimulators | Q34906036 | ||
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension | Q34917310 | ||
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In | Q34999923 | ||
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease | Q35010064 | ||
Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality | Q36734217 | ||
Mechanisms of disease: pulmonary arterial hypertension. | Q37892336 | ||
Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers | Q46562534 | ||
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat. | Q50354785 | ||
Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. | Q51331643 | ||
Pulmonary Arterial Hypertension | Q56388760 | ||
P433 | issue | Suppl 1 | |
P921 | main subject | riociguat | Q2154494 |
pharmacokinetics | Q323936 | ||
bioavailability | Q461809 | ||
P304 | page(s) | S66-74 | |
P577 | publication date | 2016-03-01 | |
P1433 | published in | Pulmonary circulation | Q26842412 |
P1476 | title | Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food | |
P478 | volume | 6 |
Q47584698 | Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat |
Q42696420 | Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects |
Q90270317 | Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects |
Q92785757 | Practical management of riociguat in patients with pulmonary arterial hypertension |
Search more.